Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 143
Filter
1.
Clin Vaccine Immunol ; 19(6): 929-34, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22539474

ABSTRACT

This study evaluated the performance of two automated Vidas (V) and Liaison (L) immunoassays for Epstein-Barr virus (EBV) serology. The detection of the viral capsid antigen (VCA) IgM, the VCA/early antigen (VCA/EA) IgG, and the Epstein-Barr nuclear antigen (EBNA) IgG was assessed on 526 sera collected for routine EBV testing in immunocompetent subjects. The determination of expected EBV status (186 EBV primary infections, 183 past EBV infections, and 157 EBV-seronegative individuals) was based on results of routine laboratory enzyme immunoassays (EIAs) together with clinical data. The sensitivity and specificity of each individual marker were determined in comparison to the expected EBV status. The agreement between the V and L profiles and the expected EBV status was established through the interpretation of combinations of the different EBV markers. Statistically significant differences between the two tests were found for the specificity of the VCA IgM marker (96.2% for V versus 93.2% for L), the sensitivity of the VCA/EA IgG marker (89% for V versus 94% for L), and the specificity of the EBNA IgG marker (96.5% for V versus 74.2% for L). The results determined for the two assays with respect to overall agreement with the established expected EBV status were not significantly different (89.7% for V versus 88.2% for L), with discrepancies mainly observed in sera referenced as primary infections. These findings demonstrated the similar performances of the Vidas and the Liaison assays for the establishment of an EBV serological status using the VCA, EA, and EBNA markers.


Subject(s)
Antibodies, Viral/blood , Automation/methods , Clinical Laboratory Techniques/methods , Epstein-Barr Virus Infections/diagnosis , Herpesvirus 4, Human/immunology , Virology/methods , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Humans , Immunoassay/methods , Immunoglobulin G/blood , Immunoglobulin M/blood , Infant , Male , Middle Aged , Sensitivity and Specificity , Young Adult
2.
HIV Med ; 13(8): 479-87, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22414000

ABSTRACT

BACKGROUND: AIDS-related lymphoma (ARL) remains the main cause of AIDS-related deaths in the combined antiretroviral therapy (cART) era. Although most ARLs are associated with the Epstein-Barr virus (EBV), whether patients with high EBV burden are more at risk of developing ARL is unknown. This study investigated the relationship between high blood EBV DNA loads and subsequent progression to ARL. METHODS: We identified 43 cases of ARL diagnosed between 1988 and 2007 within two cohorts (ANRS SEROCO/HEMOCO and PRIMO) and for which stored serum and peripheral blood mononuclear cell (PBMC) samples were available within 3 years before ARL diagnosis. For each case, two controls matched for the cohort and CD4 cell count in the year of ARL diagnosis were selected. EBV DNA was measured in PBMCs and serum samples with a commercial kit. RESULTS: High levels of EBV DNA in PBMCs collected a median of 10 months before diagnosis were associated with an increased risk of developing systemic B lymphoma (adjusted odds ratio 2.47; 95% confidence interval 1.15; 5.32 for each 1 log copies/10(6) PBMC increase in EBV load) but not with primary brain lymphoma. CONCLUSION: In this study, HIV-infected patients with undetectable EBV DNA in PBMCs did not develop ARL in the following 3 years, while high levels of EBV DNA in PBMCs predicted subsequent progression to systemic B lymphoma. Clinicians should be aware of the increased risk of developing systemic B lymphoma in HIV-infected patients with a high blood EBV DNA load.


Subject(s)
DNA, Viral/blood , HIV Infections/virology , Herpesvirus 4, Human/isolation & purification , Lymphoma, AIDS-Related/virology , Lymphoma, B-Cell/virology , Adult , Case-Control Studies , Cohort Studies , Disease Progression , Female , HIV Infections/blood , HIV Infections/complications , Herpesvirus 4, Human/genetics , Humans , Lymphoma, AIDS-Related/complications , Male , Odds Ratio , Viral Load
3.
Virologie (Montrouge) ; 11(1): 13-26, 2007 Feb 01.
Article in French | MEDLINE | ID: mdl-34753254

ABSTRACT

This review focuses on recent studies that shed new lights on infectious mononucleosis (IM). The major transmission of Epstein-Barr virus (EBV) via saliva is opposed to the possibility of sexual transmission of EBV in developed countries. Multiple infections with different LMP-1 EBV genotypes are frequently observed during IM but with unclear significance. The strict lymphotropism of the virus during primary EBV infection is questioned. Prolonged high EBV-load in saliva is clearly demonstrated during IM and could be explained by a different immune response in tonsil versus blood. Benign and severe IM are also explained by the variability of the immune response. Correlations between severity of IM and high viral load in blood are controversial. A relationship between IM and Hodgkin's disease is suggested by several epidemiological studies. Despite potential new antiviral targets and preliminary human vaccine trials, the lack of curative or preventive treatment against IM is pointed out.

4.
J Clin Microbiol ; 42(1): 242-9, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14715760

ABSTRACT

Herpes simplex virus (HSV) infections are very common in the general population and among immunocompromised patients. Acyclovir (ACV) is an effective treatment which is widely used. We deemed it essential to conduct a wide and coordinated survey of the emergence of ACV-resistant HSV strains. We have formed a network of 15 virology laboratories which have isolated and identified, between May 1999 and April 2002, HSV type 1 (HSV-1) and HSV-2 strains among hospitalized subjects. The sensitivity of each isolate to ACV was evaluated by a colorimetric test (C. Danve, F. Morfin, D. Thouvenot, and M. Aymard, J. Virol. Methods 105:207-217, 2002). During this study, 3900 isolated strains among 3357 patients were collected; 55% of the patients were immunocompetent. Only six immunocompetent patients excreted ACV-resistant HSV strains (0.32%), including one female patient not treated with ACV who was infected primary by an ACV-resistant strain. Among the 54 immunocompromised patients from whom ACV-resistant HSV strains were isolated (3.5%), the bone marrow transplantation patients showed the highest prevalence of resistance (10.9%), whereas among patients infected by human immunodeficiency virus, the prevalence was 4.2%. In 38% of the cases, the patients who excreted the ACV-resistant strains were treated with foscarnet (PFA), and 61% of them developed resistance to PFA. The collection of a large number of isolates enabled an evaluation of the prevalence of resistance of HSV strains to antiviral drugs to be made. This prevalence has remained stable over the last 10 years, as much among immunocompetent patients as among immunocompromised patients.


Subject(s)
Acyclovir/pharmacology , Antiviral Agents/pharmacology , Simplexvirus/drug effects , Adult , Aged , Aged, 80 and over , Animals , Bone Marrow Transplantation , Chlorocebus aethiops , Drug Resistance, Viral , Female , Humans , Male , Middle Aged , Organ Transplantation , Vero Cells
5.
J Clin Virol ; 28(3): 317-22, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14522070

ABSTRACT

A simplified cytomegalovirus (CMV) pp65 antigenemia assay using a one-step erythrocyte lysis, fixation and permeabilization process was compared with a standard protocol, the CMV CINAkit (Argene Biosoft) assay. The results were comparable, both quantitatively and qualitatively. The new method saves time. It also provides flexibility because the cell suspension can be stored so that test completion can be deferred if so desired.


Subject(s)
Cytomegalovirus Infections/diagnosis , Cytomegalovirus/isolation & purification , Leukocytes/virology , Phosphoproteins/blood , Viral Matrix Proteins/blood , Viremia/diagnosis , Cytomegalovirus Infections/virology , Fluorescent Antibody Technique , Humans , Reagent Kits, Diagnostic , Time Factors , Viremia/virology
6.
J Clin Virol ; 27(1): 74-82, 2003 May.
Article in English | MEDLINE | ID: mdl-12727532

ABSTRACT

BACKGROUND: With rotavirus and Norwalk-like viruses, astroviruses are now recognized as important etiologic agents of viral gastroenteritis in all age groups. However, astrovirus is neither routinely screened for in stool samples, nor in environmental samples, and data on the health impact of waterborne astrovirus are lacking. OBJECTIVES: To assess the potential impact of astrovirus in drinking water on the incidence of acute digestive conditions (ADC) among a panel of volunteers. STUDY DESIGN: The Epidemiology and MIcrobial Risk Assessment (E.MI.R.A.) study combined a daily epidemiological follow-up of digestive morbidity among a panel of 544 volunteers supplied by French public water systems, and a microbiological surveillance of drinking water. Cases of digestive morbidity were collected through weekly telephone calls. The bacterial, virological and parasitic quality of tap water was assessed monthly. Additional samples were collected if the incidence of ADC increased. The relationship between incidence of ADC during a 7-day period centered about the water sampling day and astrovirus RNA prevalence in drinking water was modeled by regression techniques, taking into account several confounders. RESULTS: 12% (8/68) of the analyzed water samples were positive for astrovirus, and presence of astrovirus RNA was associated with a significant increased risk of ADC: RR=1.51 (95% CI=[1.17-1.94], P value=0.002). CONCLUSIONS: This result suggests a role for waterborne astrovirus in the endemic level of digestive morbidity in the general population. Perhaps astrovirus is a candidate test target for viral surveillance of drinking water.


Subject(s)
Fresh Water/virology , Gastroenteritis/epidemiology , Gastroenteritis/virology , Mamastrovirus/isolation & purification , Water Supply , Acute Disease , Adolescent , Aged , Astroviridae Infections/epidemiology , Astroviridae Infections/virology , Child , Child, Preschool , Humans , Incidence , Infant , Infant, Newborn , Logistic Models , Mamastrovirus/genetics , Middle Aged , Morbidity , Risk Assessment
7.
J Neurovirol ; 9(1): 79-93, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12587071

ABSTRACT

A retroviral element (multiple sclerosis-associated retrovirus, MSRV) defining a family of genetically inherited endogenous retroviruses (human endogenous retrovirus type W, HERV-W) has been characterized in cell cultures from patients with multiple sclerosis. Recently, MSRV retroviral particles or the envelope recombinant protein were shown to display superantigen activity in vitro, but no animal model has yet been set up for studying the pathogenicity of this retrovirus. In the present study, the pathogenicity of different sources of MSRV retroviral particles has been evaluated in a hybrid animal model: severe combined immunodeficiency (SCID) mice grafted with human lymphocytes and injected intraperitoneally with MSRV virion or mock controls. MSRV-injected mice presented with acute neurological symptoms and died within 5 to 10 days post injection. Necropsy revealed disseminated and major brain hemorrhages, whereas control animals did not show abnormalities (P <.001). In ill animals, reverse transcriptase-polymerase chain reaction (RT-PCR) analyses showed circulating MSRV RNA in serum, whereas overexpression of proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma was evidenced in spleen RNA. Neuropathological examination confirmed that hemorrhages occurred prior to death in multifocal areas of brain parenchyma and meninges. Further series addressed the question of immune-mediated pathogenicity, by inoculating virion to SCID mice grafted with total and T lymphocyte-depleted cells in parallel: dramatic and statistically significant reduction in the number of affected mice was observed in T-depleted series (P <.001). This in vivo study suggests that MSRV retroviral particles from MS cultures have potent immunopathogenic properties mediated by T cells compatible with the previously reported superantigen activity in vitro, which appear to be mediated by an overexpression of proinflammatory cytokines.


Subject(s)
Cerebral Hemorrhage/virology , Endogenous Retroviruses/isolation & purification , Multiple Sclerosis/virology , T-Lymphocytes/virology , Animals , B-Lymphocytes/cytology , B-Lymphocytes/virology , Blood-Brain Barrier/immunology , Cell Death/immunology , Cells, Cultured , Cerebral Hemorrhage/immunology , Choroid Plexus/cytology , Choroid Plexus/virology , Cytokines/genetics , Disease Models, Animal , Endogenous Retroviruses/pathogenicity , Gene Expression , Humans , Mice , Mice, SCID , Multiple Sclerosis/immunology , Spleen/physiology , Spleen/virology , Superantigens/immunology , T-Lymphocytes/cytology , Virion , Virulence
8.
J Med Virol ; 65(4): 698-705, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11745934

ABSTRACT

The purpose of the present study was to assess the viral diversity of hepatitis C virus (HCV) in six nonresponder patients during three unsuccessful treatments. These patients were treated successively with IFN-alpha2a (IFN-alpha) at a posology of 3.10(6) units (MIU) three times a week, 10 MIU three times a week, and a combination of IFN-alpha (3 MIU) plus ribavirin (1,000 mg/day). However, only two chronically infected patients could be included in the study due to the persistence of HCV RNA during the three successive treatments. The viral diversity was analysed by cloning and sequencing the HVR-1 region. The treatment of the two nonresponder patients was associated with the persistence of a wide diversity in the viral population and with the emergence of new or minor variants. Under the influence of standard doses of IFN-alpha, a rearrangement of the quasispecies present was observed at this time point. No significant change in viral load or in the complexity of the quasispecies was observed. A second treatment with a high dose of IFN-alpha induced a significant decrease in the associated viral load and, in one case, resulted in a radical change of the viral diversity. Administration of a combination of IFN-alpha and ribavirin did not affect the evolution of the variants but was followed by the emergence of various multiple variants. These results reinforce the hypothesis of the presence of preexisting quasispecies best adapted to the host environment, and therefore resistant to any current therapy.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/genetics , Hepatitis C, Chronic/drug therapy , Amino Acid Sequence , Cloning, Molecular , Drug Therapy, Combination , Female , Genes, Viral , Genetic Variation , Hepacivirus/isolation & purification , Hepatitis C, Chronic/virology , Humans , Interferon alpha-2 , Interferon-alpha/therapeutic use , Male , Molecular Sequence Data , Recombinant Proteins , Ribavirin/therapeutic use , Sequence Alignment , Treatment Outcome , Viral Proteins/genetics
10.
Virology ; 287(2): 321-32, 2001 Sep 01.
Article in English | MEDLINE | ID: mdl-11531410

ABSTRACT

A retroviral element (MSRV) defining a family of genetically inherited endogenous retroviruses (HERV-W) has recently been characterized in cell cultures from patients with multiple sclerosis (MS). To address the possible relationship with MS, direct detection of circulating virion RNA was proposed but revealed technically difficult to perform in standardized conditions, in the face of multiple endogenous HERV-W copies. A parallel approach has evaluated MSRV potential pathogenicity in relation to characteristic features of multiple sclerosis, in particular, T-lymphocyte-mediated immunopathology. We report here that MSRV particles induce T-lymphocyte response with a bias in the Vbeta16 chain usage in surface receptor, whatever the HLA DR of the donor. A recombinant MSRV envelope-but not core-protein reproduced similar nonconventional activation. Molecular analysis of Vbeta CDR3 showed that Vbeta16 expansions are polyclonal. Our results thus provide evidence that MSRV envelope protein can trigger an abnormal immune response with similar characteristics to that of superantigens.


Subject(s)
Endogenous Retroviruses/immunology , Lymphocyte Activation/immunology , Multiple Sclerosis/virology , Retroviridae Infections/immunology , T-Lymphocytes/immunology , Viral Envelope Proteins/immunology , Antigens, Viral/immunology , Cells, Cultured , Cytokines/metabolism , Endogenous Retroviruses/genetics , Humans , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/virology , Multiple Sclerosis/immunology , Receptors, Antigen, T-Cell, alpha-beta/metabolism , Recombinant Proteins/immunology , Retroviridae Infections/virology , T-Lymphocytes/metabolism , Tumor Cells, Cultured , Virion/immunology
11.
Clin Infect Dis ; 33(5): 727-9, 2001 Sep 01.
Article in English | MEDLINE | ID: mdl-11477531

ABSTRACT

We present a case of documented acute hepatitis C that occurred in a health care worker who sustained a needlestick injury while caring for an individual who was infected with both hepatitis C virus (HCV) and human immunodeficiency virus (HIV). According to the findings of third-generation serological assays performed during a follow-up of >1 year, the health care worker, who was treated with interferon-alpha (during weeks 2-6) and ribavirin (during weeks 5-9), did not develop antibodies against HCV, in spite of documentation of an HCV-specific T cell response.


Subject(s)
Hepacivirus/isolation & purification , Hepatitis C Antibodies/blood , Hepatitis C/transmission , Infectious Disease Transmission, Patient-to-Professional/methods , Needlestick Injuries/virology , Adult , Antiviral Agents/therapeutic use , Follow-Up Studies , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis C/diagnosis , Hepatitis C/immunology , Hepatitis C/prevention & control , Humans , Interferon-alpha/therapeutic use , Male , Polymerase Chain Reaction , RNA, Viral/isolation & purification , Ribavirin/therapeutic use , Serologic Tests
12.
J Mol Biol ; 311(1): 217-28, 2001 Aug 03.
Article in English | MEDLINE | ID: mdl-11469870

ABSTRACT

Herpesvirus proteases are essential for the production of progeny virus. They cleave the assembly protein that fills the immature capsid in order to make place for the viral DNA. The recombinant protease of the human gamma-herpesvirus Epstein-Barr virus (EBV) was expressed in Escherichia coli and purified. Circular dichroism indicated that the protein was properly folded with a secondary structure content similar to that of other herpesvirus proteases. Gel filtration and sedimentation analysis indicated a fast monomer-dimer equilibrium of the protease with a K(d) of about 60 microM. This value was not influenced by glycerol but was lowered to 1.7 microM in the presence of 0.5 M sodium citrate. We also developed an HPLC-based enzymatic assay using a 20 amino acid residue synthetic peptide substrate derived from one of the viral target sequences for the protease. We found that conditions that stabilised the dimer also led to a higher enzymatic activity. Through sequential deletion of amino acid residues from either side of the cleavage site, the minimal peptide substrate for the protease was determined as P5-P2'. This minimal sequence is shorter than that for other herpesvirus proteases. The implications of our findings are discussed with reference to the viral life-cycle. These results are the first ever published on the EBV protease and represent a first step towards the development of protease inhibitors.


Subject(s)
Endopeptidases/chemistry , Endopeptidases/metabolism , Herpesvirus 4, Human/enzymology , Amino Acid Sequence , Antiviral Agents/chemistry , Antiviral Agents/metabolism , Chromatography, High Pressure Liquid , Circular Dichroism , Dimerization , Endopeptidases/isolation & purification , Enzyme Stability/drug effects , Glycerol/pharmacology , Herpesvirus 4, Human/growth & development , Kinetics , Mass Spectrometry , Molecular Sequence Data , Peptides/chemical synthesis , Peptides/chemistry , Peptides/genetics , Peptides/metabolism , Protease Inhibitors/chemistry , Protease Inhibitors/metabolism , Protein Binding , Protein Structure, Secondary , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Salts/pharmacology , Sequence Deletion , Structure-Activity Relationship , Substrate Specificity , Temperature , Thermodynamics , Ultracentrifugation
13.
Water Sci Technol ; 43(12): 39-48, 2001.
Article in English | MEDLINE | ID: mdl-11464767

ABSTRACT

This work assessed the risks associated with the virological quality of tapwater using a molecular analytical tool manageable in a field survey. It combined a daily epidemiological follow-up of digestive morbidity among a panel of volunteers and a microbiological surveillance of drinking water. RT-PCR was used for detection of enterovirus, rotavirus and astrovirus. 712 cases of acute digestive conditions occurred in the 544 volunteers. 38% (9/24) raw water and 23% (10/44) tap water samples were positive for at least one virus marker with 9/10 positive tap water samples complying with bacterial criteria. No statistically significant association was found between the presence of viral markers and observed incidence of digestive morbidity. However, when an outbreak occurred, enterovirus and rotavirus RNA was detected in the corresponding stored tap water samples. Sequencing of the amplified fragments showed that the rotavirus detected was of bovine origin. This work demonstrated that enteric virus markers were common in tapwater of the study communities (characterised by a vulnerable raw water) despite absence of bacterial indicators. Tangential ultrafiltration coupled to RT-PCR allowed a simultaneous and fast detection of the study viruses from environmental samples. This process is a promising tool usable for virological water surveillance, in as much the corresponding know-how is transferred to the field professionals.


Subject(s)
DNA, Viral/analysis , Disease Outbreaks , Gastrointestinal Diseases/virology , Reverse Transcriptase Polymerase Chain Reaction , Viruses , Water Purification , Water Supply , Adolescent , Biomarkers/analysis , Child , Child, Preschool , Environmental Monitoring/methods , Epidemiological Monitoring , Female , Gastrointestinal Diseases/epidemiology , Health Surveys , Humans , Incidence , Infant , Infant, Newborn , Male , Public Health , Quality Control , Risk Assessment
14.
J Clin Virol ; 22(1): 125-31, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11418360

ABSTRACT

BACKGROUND: the reference method to study the HCV complexity was cloning and sequence analysis of a sufficient number of clones. The evolution of the viral complexity in chronic non responder patients during treatment with standard doses of interferon was not very well investigate because this method was expensive and labour intensive when large series of patients were concerned. Meanwhile, with the alternative Single-Strand Conformation Polymorphism (SSCP) method, a rough estimation of the quasispecies present in a given sample could be obtained. OBJECTIVES: the aim of the study was to analyse the evolution of HCV heterogeneity, investigated by SSCP analysis targeted to the HVR-1, in 30 nonresponders chronic hepatitis C patients treated by Interferon-alpha 3MUI. RESULTS: genotype 1 was the main HCV type found in this population (77% of non responder patients). Before treatment, the SSCP assay revealed a high complexity pattern: the median of SSCP band number was 9. During IFN-alpha treatment, SSCP band number didn't change. However a significant decrease of the viral load was observed (P<0.01). Patients with variations in their SSCP patterns after therapy significantly decreased HCV RNA levels (P<0.002). In one third of patients the SSCP profile didn't change at all. CONCLUSIONS: we observed that viral heterogeneity didn't change in non responder chronic hepatitis C patients during IFN-alpha treatment. Nevertheless patients with a low number of pre-treatment quasispecies exhibited an improvement of the response (P<0.02). These phenomena were probably due to a selection of resistant variants present prior onset of therapy.


Subject(s)
Hepacivirus/genetics , Hepatitis C, Chronic/virology , Interferon-alpha/therapeutic use , Adult , Aged , Alanine Transaminase/blood , Female , Genetic Heterogeneity , Hepacivirus/drug effects , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/drug therapy , Humans , Male , Middle Aged , Polymorphism, Single-Stranded Conformational , Prospective Studies , RNA, Viral/analysis , Treatment Failure
15.
Br J Cancer ; 84(6): 783-90, 2001 Mar 23.
Article in English | MEDLINE | ID: mdl-11259092

ABSTRACT

Since the few data exploring a possible association between Epstein-Barr virus (EBV) and breast cancer are conflicting, we investigated this association together with the influences of geographical areas. 509 breast cancers were sampled from areas with varying risks of nasopharynx carcinoma (NPC) such as North Africa (Algeria and Tunisia, high-risk area); southern France (Marseille, intermediate-risk area); and northern Europe (northern France, the Netherlands and Denmark; low-risk areas). Polymerase chain reaction (PCR) of a subregion of EBV BamHIC encoding the EBERs demonstrated that 31.8% of the tumours contained the viral genome. No significant differences were observed among the geographical areas. However, positive samples showed higher loads of the EBV genome in the NPC high- and intermediate-risk areas than in the low-risk areas. EBV type 1 was the dominant strain. In situ hybridization studies using a(35)S-labelled riboprobe for EBER1 and a laser capture microdissection, combined with quantitative PCR, showed that EBV localization was restricted to some tumour epithelial cell clusters. EBV could not be detected in the stroma. Considering the whole population covered, the presence of the EBV genome was not correlated with age, menopausal status, tumour, size, nodal status or histological grade.


Subject(s)
Breast Neoplasms/virology , Carcinoma, Ductal, Breast/virology , Genome, Viral , Herpesvirus 4, Human/isolation & purification , Adult , Africa, Northern , Base Sequence , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , DNA Primers , Europe , Female , Herpesvirus 4, Human/genetics , Humans , In Situ Hybridization , Lasers , Middle Aged , Polymerase Chain Reaction/methods
16.
Blood ; 97(6): 1590-7, 2001 Mar 15.
Article in English | MEDLINE | ID: mdl-11238096

ABSTRACT

Severe T-cell immunodeficiency after solid organ or bone marrow transplantation may result in the uncontrolled outgrowth of latently Epstein-Barr virus-infected B cells, leading to B-lymphoproliferative disorder (BLPD). Given the potentially important pathogenic role of IL-6 in BLPD, it was tested whether the in vivo neutralization of IL-6 by a monoclonal anti-IL-6 antibody could contribute to the control of BLPD. Safety and efficacy were assessed in 12 recipients of transplanted organs who had BLPD refractory to the reduction of immunosuppression over 8 days. Five patients received 0.4 mg/kg per day. The next 7 patients received 0.8 mg/kg per day. Treatment was scheduled to last 15 days. It was completed in 10 patients, and in the other 2 patients was discontinued early (days 10 and 13, respectively) because of disease progression. Treatment tolerance was good, and no major side effects were observed. High C-reactive protein levels were found in 9 patients before treatment but were normalized under treatment in all patients, demonstrating efficient IL-6 neutralization. Complete remission (CR) was observed in 5 patients and partial remission (PR) in 3 patients. Relapse was observed in 1 of these 8 patients in whom remission was observed. This relapse was unresponsive to treatment. Disease was stable in 1 patient, but it progressed in 3 patients. Seven patients are alive and well. Two patients died because of disease progression, and 3 patients died while in CR (chronic rejection in 2 patients and BLPD sequelae in 1 patient). These data suggest that the anti-IL-6 antibody is safe and should be further explored in the treatment of BLPD.


Subject(s)
Antibodies, Monoclonal/therapeutic use , B-Lymphocytes/pathology , Interleukin-6/immunology , Lymphoproliferative Disorders/drug therapy , Adolescent , Adult , Antibodies, Monoclonal/pharmacokinetics , Antibodies, Viral/blood , C-Reactive Protein/metabolism , Child , Child, Preschool , Female , Herpesvirus 4, Human/genetics , Humans , Infant , Interleukin-6/blood , Lymphoproliferative Disorders/blood , Lymphoproliferative Disorders/etiology , Male , Middle Aged , Therapeutic Equivalency , Tissue Transplantation/adverse effects , Treatment Outcome
17.
Clin Diagn Lab Immunol ; 8(2): 429-31, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11238233

ABSTRACT

An easy, rapid, and reproducible test to distinguish residual cytomegalovirus (CMV) immunoglobulin M (IgM) antibodies from antibodies produced in primary infection could be useful, especially for pregnant women. The CMV avidity of IgG antibodies with the VIDAS automated enzyme-linked fluorescent assay and 6 M urea was evaluated in a multicenter study to differentiate between primary CMV infections and past infections or reactivations. A total of 416 serum specimens were tested: 159 specimens were from follow-up of primary infections, and 257 were from past infections. All of the specimens from primary infections collected within 4 months (17 weeks) after the onset of the infection had an avidity index lower than 0.8. An avidity index higher than 0.8 excludes a recent primary infection of less than 4 months. However, an avidity index higher than 0.8 cannot confirm all past infections, since 48 specimens (18%) from past infections had an avidity index lower than 0.8 (between 0.5 and 0.8). The exclusion capacity could be improved (96.9%) by using a cutoff of 0.7, but this index would decrease the specificity of the technique, since the avidity index was found to be between 0.7 and 0.8 in two patients with recent primary infection. All specimens from primary infections obtained more than 4 months after the onset of infection had an avidity index more than 0.2. In this study, an avidity index less than 0.2 confirms the presence of a recent primary infection of less than 4 months. The VIDAS CMV IgG avidity test is a rapid, reproducible test with very good performance.


Subject(s)
Antibody Affinity , Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/immunology , Cytomegalovirus/immunology , Immunoenzyme Techniques/methods , Immunoglobulin G/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Evaluation Studies as Topic , Female , Humans , Immunoenzyme Techniques/standards , Immunoglobulin G/blood , Kinetics , Pregnancy , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/virology , Reproducibility of Results
18.
Hepatology ; 33(1): 207-17, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11124838

ABSTRACT

Human apolipoprotein H (apo H) was found to bind specifically to hepatitis B surface antigen (HBsAg) from hepatitis B virus (HBV)-infected individuals. We used recombinant HBsAg proteins to analyze HBV domains recognized by apo H. We showed that the myristylated pre-S1 domain of HBsAg strongly interacted with apo H. This binding involved phospholipid components of the HBV envelope because their removal by detergent prevented apo H-HBsAg interaction. The opposite effects of iron and zinc metal ions on binding suggest that the oxidation of phospholipids also affects apo H-HBsAg interaction. After fractionation of viral particles on a sucrose gradient, and their addition to microtiter plates coated with apo H or anti-HBsAg, we observed that the maximal anti-HBsAg capture activity corresponded to a sucrose concentration of 36%, whereas the maximal apo H capture activity corresponded to a concentration of 39%. Electron microscopy and polymerase chain reaction (PCR) Southern blot studies of these fractions showed that the fraction with maximal apo H binding predominantly contained full Dane particles. Finally, we studied apo H-HBsAg binding relative to the presence of hepatitis B virus markers and observed that apo H binding activity for HBsAg was higher in sera from patients in the active virus replication phase.


Subject(s)
Glycoproteins/metabolism , Hepatitis B virus/metabolism , Animals , Blotting, Southern , Cell Line , DNA, Viral/metabolism , Glycoproteins/blood , Hepatitis B Surface Antigens/blood , Hepatitis B Surface Antigens/chemistry , Hepatitis B Surface Antigens/metabolism , Hepatitis B virus/genetics , Humans , Immunoenzyme Techniques , Macromolecular Substances , Microscopy, Electron , Oxidation-Reduction , Phospholipids/metabolism , Polymerase Chain Reaction , Recombinant Proteins/blood , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Spodoptera/cytology , beta 2-Glycoprotein I
19.
Rheumatology (Oxford) ; 39(9): 950-4, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10986298

ABSTRACT

OBJECTIVES: To determine whether the recently identified multiple sclerosis-associated retrovirus, MSRV, is detectable in the serum and synovial fluid of patients with rheumatoid arthritis (RA). METHODS: A reverse transcription-polymerase chain reaction (RT-PCR) assay was used to seek evidence of particle-associated MSRV/HERV-W RNA in the plasma and synovial fluid of patients with RA and controls. Stringent precautions were taken to avoid detection of contaminating human genomic DNA and cellular RNA sequences. RESULTS: Thirty-seven plasma samples were tested (20 from RA patients and 17 from controls) but none had detectable MSRV/HERV-W RNA. Synovial fluid samples were available from nine patients with RA and 10 controls. Particle-associated MSRV/HERV-W RNA was reproducibly detected in two of nine synovial fluid samples from RA patients and in one control sample. The identity of RT-PCR products was confirmed by sequencing. CONCLUSION: MSRV/HERV-W RNA sequences are detectable in the synovial fluid of a small proportion of RA patients, but this phenomenon may not be specific to RA.


Subject(s)
Arthritis, Rheumatoid/virology , Multiple Sclerosis/virology , RNA/analysis , Retroviridae/genetics , Synovial Fluid/chemistry , Humans
20.
Appl Environ Microbiol ; 66(6): 2690-2, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10831460

ABSTRACT

Reverse transcription-PCR analysis of drinking water in the homes of 56 children suffering from rotaviral gastroenteritis has shown the presence of the rotavirus genome in four samples. These strains were different from human rotaviruses detected in the children's feces, as determined by sequencing of the VP7-amplified fragments-three of them of animal origin (porcine or bovine) and one of human origin.


Subject(s)
Antigens, Viral , Capsid Proteins , Gastroenteritis/virology , Rotavirus Infections/virology , Rotavirus/genetics , Rotavirus/isolation & purification , Water Microbiology , Water Supply , Amino Acid Sequence , Animals , Capsid/chemistry , Capsid/genetics , Cattle , Child , Drinking , Feces/virology , Humans , Molecular Sequence Data , Reverse Transcriptase Polymerase Chain Reaction , Rotavirus/classification , Sequence Analysis, DNA , Swine
SELECTION OF CITATIONS
SEARCH DETAIL
...